Management challenges for chronic dysimmune neuropathies during the COVID-19 pandemic
| Autor: | Yusuf A. Rajabally, Shahram Attarian, Hans-Peter Hartung, H. Stephan Goedee |
|---|---|
| Přispěvatelé: | University Hospitals Birmingham [Birmingham, Royaume-Uni], Aston University [Birmingham], University Medical Center [Utrecht], Reference Centre for Neuromuscular Diseases and ALS [Marseille], Hôpital de la Timone [CHU - APHM] (TIMONE), Marseille medical genetics - Centre de génétique médicale de Marseille (MMG), Aix Marseille Université (AMU)-Institut National de la Santé et de la Recherche Médicale (INSERM), Heinrich Heine Universität Düsseldorf = Heinrich Heine University [Düsseldorf], Y.A.R. has received speaker/consultancy honoraria from CSL Behring, LFB, Grifols, BPL, Octapharma, and Kedrion, has received educational sponsorships from LFB, CSL Behring and Baxter and has obtained research grants from CSL Behring and LFB, H.S.G. has received research grants from Prinses Beatrix Spierfonds (W.OR14.08 and W.OR17-21), and received speaker fee/travel grants from Shire/Baxalta.S.A. has received speaker/consultancy honoraria from LFB, Alnylam, Akcea, Pfizer, Pharnext, Sanofi, and Biogen, has received educational sponsorships from LFB, and has obtained research grants from and LFB and Pfizer. H.P.H. received fees for serving on steering committees and advisory boards from CSL Behring, LFB, Octapharma, Roche, UCB., Bodescot, Myriam |
| Jazyk: | angličtina |
| Rok vydání: | 2020 |
| Předmět: |
0301 basic medicine
medicine.medical_specialty Coronavirus disease 2019 (COVID-19) Physiology multifocal motor neuropathy [SDV.NEU.NB]Life Sciences [q-bio]/Neurons and Cognition [q-bio.NC]/Neurobiology Pneumonia Viral Clinical Neurology 030105 genetics & heredity Best interests Betacoronavirus Polyneuropathies 03 medical and health sciences Cellular and Molecular Neuroscience chronic inflammatory demyelinating polyneuropathy Autoimmune Diseases of the Nervous System 0302 clinical medicine paraproteinemic neuropathy COVID‐19 Physiology (medical) Pandemic Humans Medicine Intensive care medicine Pandemics [SDV.MP.VIR] Life Sciences [q-bio]/Microbiology and Parasitology/Virology [SDV.MHEP.ME] Life Sciences [q-bio]/Human health and pathology/Emerging diseases [SDV.MHEP.ME]Life Sciences [q-bio]/Human health and pathology/Emerging diseases SARS-CoV-2 business.industry Public health pandemic [SDV.NEU.NB] Life Sciences [q-bio]/Neurons and Cognition [q-bio.NC]/Neurobiology Disease Management COVID-19 Issues & Opinions 3. Good health dysimmune Steroid therapy [SDV.MP.VIR]Life Sciences [q-bio]/Microbiology and Parasitology/Virology Infectious risk Neurology (clinical) Objective evaluation Coronavirus Infections business 030217 neurology & neurosurgery |
| Zdroj: | Muscle & nerve. Supplement. Muscle & nerve. Supplement., 2020, ⟨10.1002/mus.26896⟩ Muscle & Nerve |
| DOI: | 10.1002/mus.26896⟩ |
| Popis: | International audience; Since March 2020, the COVID-19 pandemic has led to the need to re-think the delivery of services to patients with chronic dysimmune neuropathies. Telephone/video consultations have become widespread but have compounded concerns about objective evaluation. Therapeutic decisions need, more than ever before, to be considered in the best interests of both patients, and society, while not denying function-preserving/restoring treatment. Immunoglobulin therapy and plasma exchange, for those treated outside of the home, expose patients to the hazards of hospital or outpatient infusion centers. Steroid therapy initiation and continuation pose increased infectious risk. Immunosuppressant therapy similarly becomes highly problematic, with the risks of treatment continuation enhanced by uncertainties regarding duration of the pandemic. The required processes necessitate considerable time and effort especially as resources and staff are re-deployed to face the pandemic, but are essential for protecting this group of patients and as an integral part of wider public health actions. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|